Jackson Creek Investment Advisors LLC Purchases Shares of 9,045 Exelixis, Inc. (NASDAQ:EXEL)

Jackson Creek Investment Advisors LLC bought a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 9,045 shares of the biotechnology company's stock, valued at approximately $301,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Stephens Inc. AR acquired a new position in Exelixis during the 3rd quarter worth approximately $251,000. Farther Finance Advisors LLC raised its position in shares of Exelixis by 467.7% during the third quarter. Farther Finance Advisors LLC now owns 3,940 shares of the biotechnology company's stock worth $102,000 after purchasing an additional 3,246 shares during the period. Van ECK Associates Corp lifted its holdings in shares of Exelixis by 66.2% in the 3rd quarter. Van ECK Associates Corp now owns 173,584 shares of the biotechnology company's stock worth $4,916,000 after purchasing an additional 69,134 shares in the last quarter. QRG Capital Management Inc. grew its position in Exelixis by 6.4% in the 3rd quarter. QRG Capital Management Inc. now owns 54,879 shares of the biotechnology company's stock valued at $1,424,000 after purchasing an additional 3,321 shares during the period. Finally, Capital Performance Advisors LLP bought a new stake in Exelixis during the 3rd quarter valued at $61,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Performance

EXEL stock traded up $0.27 during midday trading on Wednesday, reaching $37.20. 2,750,774 shares of the company's stock traded hands, compared to its average volume of 2,087,863. The firm has a market capitalization of $10.41 billion, a PE ratio of 21.02, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The company has a 50-day moving average price of $35.18 and a two-hundred day moving average price of $32.29. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02.

Remove Ads

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Ratings Changes

EXEL has been the topic of a number of recent research reports. Bank of America lowered shares of Exelixis from a "buy" rating to a "neutral" rating and raised their price objective for the company from $35.00 to $39.00 in a research note on Tuesday, December 17th. Oppenheimer downgraded Exelixis from an "outperform" rating to a "market perform" rating and cut their price target for the company from $41.00 to $33.00 in a research note on Friday, January 24th. Stephens restated an "equal weight" rating and issued a $29.00 target price on shares of Exelixis in a report on Wednesday, February 12th. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Exelixis in a report on Thursday, February 13th. Finally, Morgan Stanley upgraded shares of Exelixis from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $30.00 to $40.00 in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $37.24.

Insider Buying and Selling

In other news, Director Mary C. Beckerle sold 12,210 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the transaction, the director now owns 30,406 shares of the company's stock, valued at $1,060,561.28. This represents a 28.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total transaction of $388,000.00. Following the sale, the executive vice president now directly owns 341,028 shares of the company's stock, valued at $13,231,886.40. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock worth $5,177,234 over the last ninety days. 2.85% of the stock is owned by corporate insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.